ORIGINAL ARTICLE

The prognostic value of progesterone receptor status in meningiomas

F Roser¹, M Nakamura², M Bellinzona², S K Rosahl³, H Ostertag⁴, M Samii⁵

¹ Department of Neurosurgery, University of Tübingen, 72076, Tübingen, Germany
² Department of Neurosurgery, Klinikum Hannover Nordstadt, 30167 Hannover, Germany
³ Department of Neurosurgery, University of Freiburg, 79106 Freiburg, Germany
⁴ Institute of Pathology, Klinikum Hannover Nordstadt
⁵ International Neuroscience Institute, 30625 Hannover, Germany

Correspondence to:
Correspondence to:
Dr F Roser
Department of Neurosurgery, University of Tübingen, Hoppe-Seyler Str.3, 72076, Tübingen, Germany; f.roser{at}gmx.de

Background: Meningiomas are known to recur frequently, and their longterm management remains controversial. Previous studies indicate that progesterone and its receptors can play a role in the recurrence of meningiomas, but the correlation between the presence of these receptors and patients’ outcome is unclear.

Aim: To conduct a retrospective analysis to investigate the prognostic relevance of progesterone receptor (PR) expression in meningiomas.

Methods: Five hundred and eighty eight meningiomas operated on over a period of 10 years were examined immunohistochemically to determine the PR status using monoclonal antibodies. Several factors including recurrence (mean follow up of 65 month), sex, tumour tissue consistency, location, vascularity, and en plaque appearance were analysed.

Results: PR status showed comparable values for men and women. World Health Organisation (WHO) grade II and III tumours had significantly fewer receptors than benign meningiomas. There was no significant correlation between PR status and recurrence rates in WHO grade I totally removed meningiomas. However, a combination of PR status and proliferation indices was shown to predict recurrence reliably.

Conclusions: Together with routine histological evaluation, PR status can help to describe the biological behaviour of meningiomas. Only a combination of clinical and biological features can describe the behaviour of meningiomas, predict their recurrence, and help to devise more effective follow up strategies.

Abbreviations: IRS, immunoreactive score; LI, labelling index; NF-II, neurofibromatosis type 2; PR, progesterone receptor; WHO, World Health Organisation

Keywords: meningioma; recurrence; proliferation; progesterone; receptor

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Chargari, C., Vedrine, L., Bauduceau, O., Le Moulec, S., Ceccaldi, B., Magne, N. (2008). Reapprasial of the role of endocrine therapy in meningioma management. Endocr Relat Cancer 15: 931-941 [Abstract] [Full Text]  
• Claus, E. B., Park, P. J., Carroll, R., Chan, J., Black, P. M. (2008). Specific Genes Expressed in Association with Progesterone Receptors in Meningioma. Cancer Res. 68: 314-322 [Abstract] [Full Text]  
• Maillo, A., Orfao, A., Espinosa, A. B., Sayagues, J. M., Merino, M., Sousa, P., Lara, M., Tabernero, M. D. (2007). Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone. Neuro Oncol Duke 9: 438-446 [Abstract] [Full Text]  
• Tabernero, M. D., Espinosa, A. B., Maillo, A., Rebelo, O., Vera, J. F., Sayagues, J. M., Merino, M., Diaz, P., Sousa, P., Orfao, A. (2007). Patient Gender Is Associated with Distinct Patterns of Chromosomal Abnormalities and Sex Chromosome Linked Gene-Expression Profiles in Meningiomas. The Oncologist 12: 1225-1236 [Abstract] [Full Text]  
• Yrjana, S.K., Tuominen, H., Karttunen, A., Lahdesluoma, N., Heikkinen, E., Koivukangas, J. (2006). Low-Field MR Imaging of Meningiomas Including Dynamic Contrast Enhancement Study: Evaluation of Surgical and Histopathologic Characteristics. Am. J. Neuroradiol. 27: 2128-2134 [Abstract] [Full Text]  
• Wigertz, A., Lonn, S., Mathiesen, T., Ahlbom, A., Hall, P., Feychting, M., and the Swedish INTERPHONE Study Group, (2006). Risk of Brain Tumors Associated with Exposure to Exogenous Female Sex Hormones. Am J Epidemiol 164: 629-636 [Abstract] [Full Text]